Cytokinetics Inc

NASDAQ:CYTKUnited States

Cytokinetics Inc. is a late-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases. It is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. The Company's clinical-stage drug candidates are: omecamtiv mecarbil, a cardiac myosin activator for the treatment of heart failure with reduced ejection fraction (HFrEF); CK-136, a cardiac troponin activator for the treatment of heart failure and other diseases; reldesemtiv , a fast skeletal muscle troponin activator (FSTA) for the treatment of people living with debilitating diseases and conditions associated with muscular weakness; aficamten, a cardiac myosin inhibitor designed to reduce the hypercontractility that is associated with hypertrophic cardiomyopathy (HCM); and CK-136 an novel small molecule cardiac troponin activator.

Contact Information

Headquarters

350 Oyster Point BoulevardSOUTH SAN FRANCISCO, CA, United States 94080

Phone

650-624-3000

Fax

650-624-3010

Executives

Independent Chairman of the Board

John Henderson

President, Chief Executive Officer, Director

Robert Blum

Chief Financial Officer, Senior Vice President

Ching Jaw

Executive Vice President, Chief Commercial Officer

Andrew Callos

Executive Vice President - Research and Development

Fady Malik